2013 pay: $16.9 million
2012 pay: $11 million
Alex Gorsky started with Janssen Pharmaceuticals in 1988 as a sales rep and worked his way up the corporate ladder at Johnson & Johnson ($JNJ), becoming president of that unit in 2001. Then, Gorsky served as company group chairman of the J&J pharmaceutical business in Europe, the Middle East and Africa, and from there left for Novartis ($NVS) for a brief, four-year stint. But he came back to J&J in 2008, taking up top posts in J&J's diagnostics and devices businesses before being named CEO in 2012 and chairman later that year.
Last year, J&J was the subject of speculation when Gorsky said the company was considering selling its underperforming $2.2 billion testing arm, Ortho Clinical Diagnostics. At the beginning of 2014, J&J struck a deal with private equity firm Carlyle Group to buy the unit for $4.1 billion.
In 2013, Gorsky helped boost profit for J&J's devices and diagnostics units, which account for more than half of the company's revenues at $28.5 billion, by nearly 4%. However, while med tech sales produced solid gains in 2013 overall, divisions such as diabetes care and diagnostics slumped in the fourth quarter last year.
Gorsky has said that the company is gradually adjusting its strategy when it comes to doing business in med tech and has investor patience when it comes to devices and diagnostics, saying the company hasn't yet procured the full benefits of its blockbuster Synthes deal.
Gorsky earned $16.9 million in 2013, a signficant 55% more than in 2012. He brought home $1.4 million in base salary, $5.9 million in stock awards, $2.6 million in options, $4.8 million in nonequity incentives, $191,779 in other pay and $1.7 million in nonqualified deferred compensation. -- Emily Mullin (email | Twitter)
- here's Johnson & Johnson's proxy statement
J&J will sell Ortho Clinical Diagnostics to Carlyle for $4B plus
J&J's med tech biz falters amid weak sales, M&A rumors